In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the contributors are unable to tolerate the study drugs. Achievable new strategies for your prognosis and treatment of AML. (A) The identification https://abbv-744-brd4-inhibitor-m01346.humor-blog.com/31222967/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison